633335-80-5

Basic information

• Product Name: N-(4-BroMo-5-fluoro-2-Methylphenyl)acetaMide
• Synonyms: N-(4-BroMo-5-fluoro-2-Methylphenyl)acetaMide;AcetaMide, N-(4-broMo-5-fluoro-2-Methylphenyl)-
• CAS NO: 633335-80-5
• Molecular Formula: C₉H₉BrFNO
• Molecular Weight: 246.0762632
• Mol File: 633335-80-5.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-BroMo-5-fluoro-2-Methylphenyl)acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-BroMo-5-fluoro-2-Methylphenyl)acetaMide(633335-80-5)
• EPA Substance Registry System: N-(4-BroMo-5-fluoro-2-Methylphenyl)acetaMide(633335-80-5)

Safety Data

• Hazardous Substances Data: 633335-80-5(Hazardous Substances Data)

Upstream product

• 52723-82-7 4-bromo-5-fluoro-2-methylaniline 
• 108-24-7 acetic anhydride 
• 367-29-3 3-fluoro-6-methylaniline 
• 366-49-4 5’-fluoro-2’-methylacetanilide 

Downstream Products

• 633335-81-6 1-(5-bromo-6-fluoro-1H-indazol-1-yl)ethan-1-one 
• 1086836-99-8 4-Bromo-3-fluoro-6-methyl-2-nitroaniline 
• 1126425-15-7 6-fluoro-1H-indazole-5-carbaldehyde 
• 105391-70-6 5-bromo-6-fluoro-1H-indazole 

Relevant articles and documents

3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS

The present invention relates to compounds of Formula (I), and Formula (II), wherein B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH2)2-triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from -C1-3 alkyl, -O-C1-3 alkyl, CN, - (CH2)2-O-(CH2)2-OR4 and halo; and D is -C(O)OH, -C(O)NHSO2CH3, -SO2NHC(O)CH3, 5-(trifluoromethyl)-4H-1,2,4-triazol-2-yl, or tetrazolyl; and their use as NRF2 regulators.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.